Biosimilar development process
Biosimilar medicines represent an important advancement in healthcare, offering greater patient access to biological therapies that might otherwise be cost-prohibitive. The biosimilar development process revolves around a comprehensive comparability assessment between the proposed biosimilar and its reference biological product. The primary goal of the development process isn’t to establish the efficacy and safety of the […]
Advancing biologics manufacturing
Optimize biologics manufacturing with Recombinant Insulin—enhancing cell growth, yield, and process consistency for therapeutic production.
The Insulin peptide family
Monoclonal antibodies | Viral vectors for gene therapy | Cell-based vaccinees | Pluripotent stem cells
The insulin and IGF-1 receptors
Monoclonal antibodies | Viral vectors for gene therapy | Cell-based vaccinees | Pluripotent stem cells
How insulin and IGF-1 bind to their receptors
Monoclonal antibodies | Viral vectors for gene therapy | Cell-based vaccinees | Pluripotent stem cells
Insulin and IGF-1 receptor signalling pathways: Where is the specificity?
Monoclonal antibodies | Viral vectors for gene therapy | Cell-based vaccinees | Pluripotent stem cells
A short history of cell culture media and the use of insulin
Monoclonal antibodies | Viral vectors for gene therapy | Cell-based vaccinees | Pluripotent stem cells
How cells grow, the discovery of Insulin like growth factors
Monoclonal antibodies | Viral vectors for gene therapy | Cell-based vaccinees | Pluripotent stem cells
Regulation of apoptosis by insulin and IGF-1
Monoclonal antibodies | Viral vectors for gene therapy | Cell-based vaccinees | Pluripotent stem cells
Regulation of the cell cycle by insulin and IGF1
Monoclonal antibodies | Viral vectors for gene therapy | Cell-based vaccinees | Pluripotent stem cells
